<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269476</url>
  </required_header>
  <id_info>
    <org_study_id>SNX-001-PH1-09</org_study_id>
    <secondary_id>2009-011335-13</secondary_id>
    <nct_id>NCT01269476</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers</brief_title>
  <official_title>Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeneXta Therapeutics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeneXta Therapeutics SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, group-sequential, placebo-controlled, safety and
      pharmacokinetic study in healthy, aged volunteers.

      Objectives:

        1. to confirm the previously reported safety profile of oral SNX-001 after single and
           multiple doses of 3.6, 7.2 or 10.8 mg compared to placebo

        2. to establish SNX-001 pharmacokinetic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an exploratory study designed as a group sequential single and multiple
      escalating dose, double-blind within cohort, randomized, placebo controlled study to
      investigate the safety and tolerability as well as the pharmacokinetics and pharmacodynamics
      of SNX-001 given as oral doses in aged volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship of clinical safety measurements to dose</measure>
    <time_frame>Throughout 14-day study period (Days 1, 2, 3, 10, 12, 13, 14) and 7 days after last dose (Day 21)</time_frame>
    <description>Adverse events (AEs), vital signs, electrocardiogram (ECG), Acetylcholinesterase (AChE) inhibition, laboratory parameters after single and multiple dose administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of dose on pharmacokinetic (PK) parameters</measure>
    <time_frame>After single (Day 1) and multiple (Day 12) doses</time_frame>
    <description>Pharmacokinetic parameters after single and multiple dose administration of SNX-001 (3.6, 7.2 and 10.8 mg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>SNX-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNX-001</intervention_name>
    <description>3.6, 7.2, or 10.8 mg single dose or t.i.w.</description>
    <arm_group_label>SNX-001</arm_group_label>
    <other_name>methanesulfonyl fluoride</other_name>
    <other_name>MSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same volumes and frequency as active.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Oil vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females

          -  Physically and mentally healthy subjects

          -  Body weight &gt;60 kg and body weight â‰¤ 100 kg

        Exclusion Criteria:

          -  Evidence of any clinically significant hepatic, renal, gastrointestinal,
             cardiovascular, pulmonary, haematological, psychiatric, neurological or other
             significant acute or chronic abnormalities

          -  History of general malignant diseases

          -  Evidence of myasthenic weakness

          -  Acute infection or any other febrile illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorg Sahlmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scope Life Sciences GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scope Life Sciences GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>December 31, 2010</last_update_submitted>
  <last_update_submitted_qc>December 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Enrico Braglia</name_title>
    <organization>SeneXta Therapeutics SA</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methanesulfonyl fluoride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

